Reuters logo
3 个月内
BRIEF-Enanta announces eight weeks of treatment with Abbvie's investigational drug achieved high SVR rates in challenging-to-treat genotype 3 chronic HCV patients
2017年4月21日 / 上午10点44分 / 3 个月内

BRIEF-Enanta announces eight weeks of treatment with Abbvie's investigational drug achieved high SVR rates in challenging-to-treat genotype 3 chronic HCV patients

1 分钟阅读

April 21 (Reuters) - Enanta Pharmaceuticals Inc

* Enanta announces eight weeks of treatment with Abbvie's investigational, pan-genotypic, ribavirin-free HCV regimen of glecaprevir/pibrentasvir (g/p) achieved high SVR rates in challenging-to-treat genotype 3 chronic HCV patients

* Enanta - 95 percent patients with genotype 3 chronic hepatitis c virus , without cirrhosis, new to treatment achieved svr(12) with 8 weeks of treatment

* Enanta Pharmaceuticals Inc says in endurance-3 study, no patients who received 8 weeks of g/p discontinued treatment due to adverse events Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below